OncoLize
Investors
Investors
This is a magnificent opportunity for reward and for impact in oncology
You have heard it all before, we are sure of that. So, we derisked the ChemoGell™ proposition to a considerable length and kept it attractive to step in early and make your ROI count. Even better, we are going to prove this to you with our lead product ChemGemTM , dealing with one of the most notorious cancers out there: Pancreatic Cancer, more specifically PDAC.
Our highly motivated and well-informed lead investor joins our current shareholders and other co-investors to close the Seed B round of €2.8 mln. This money will take us into the First-in-Patient and Phase 1/2 clinical trials in Pancreatic Cancer, performed by one of the top global Key Opinion Leaders and his European colleagues.
This could be followed by a Series A of up to €17 million with which we expand the trials and develop additional Product Market Combinations in Difficult to Treat Tumor diseases.
Investors seeking impact and healthy return, join us!
The planned investment period is 4-5 years. We foresee an exit in a trade sale or a possible IPO.
Interested to get in touch with us? Please use the contact form in contact page.
In total we foresee two investment rounds to accelerate value and impact
Series A of €10+ Million.This can bring us up to different Phase I/II trials in patients both in EU and USA. The Scale-up of the products is ready for early commercial scale. We will have identified multiple opportunities for out-licensing the developed products to specialized Oncology marketeers.
Series B of €30+ Million. With this round we will be able to finalize registration of up to 3 products ready for market launch and licensing to specialized Oncology marketeers. In addition a product pipeline will be (co-)developed with a selection of off-patent and novel drugs. With this investment round we secure the optimum value for an Exit.
Pioneers and other chemo delivery companies with documented exits show valuations between 100 Million to 1 Billion US$ based on older concepts.
We have clear USP’s over these for marketeers, doctors and patients.
Impact Investment
We also make sure that our products will become available for Low Income Countries in what we call our Triple A – products: Affordable and Accessible for All . We do this through collaborations with relevant NGO’s operating in LMICs and targeting Oncology.
